CytomX Therapeutics, Inc.
NASDAQ:CTMX
Overview | Financials
Company Name | CytomX Therapeutics, Inc. |
Symbol | CTMX |
Currency | USD |
Price | 1 |
Market Cap | 78,117,600 |
Dividend Yield | 0% |
52-week-range | 0.98 - 5.85 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Sean A. McCarthy D.Phil., DPHIL |
Website | https://www.cytomx.com |
An error occurred while fetching data.
About CytomX Therapeutics, Inc.
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD